• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过体检早期检测常染色体显性多囊肾病

Detection of Autosomal Dominant Polycystic Kidney Disease by Medical Checkup at an Early Stage.

作者信息

Fukunaga Shohei, Kamei Fumika, Sonoda Hirotaka, Oba Masafumi, Kawanishi Miharu, Egawa Masahiro, Ito Takafumi, Tanabe Kazuaki

机构信息

Internal Medicine IV, Shimane University Faculty of Medicine, Izumo, JPN.

出版信息

Cureus. 2021 Oct 8;13(10):e18595. doi: 10.7759/cureus.18595. eCollection 2021 Oct.

DOI:10.7759/cureus.18595
PMID:34765359
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8572515/
Abstract

INTRODUCTION

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disease. Although abdominal echography during medical checkup may be effective for the early detection of ADPKD, there are no reports of the early detection of ADPKD during medical checkup. We investigated whether there was a difference in renal function and total kidney volume (TKV) at the time of diagnosis due to differences in diagnostic triggers for ADPKD.

METHODS

A total of 34 patients diagnosed with ADPKD between January 1, 2010, and December 31, 2020, at the Department of Nephrology, Shimane University Hospital, were included. The triggers for diagnosis of the renal cyst(s) were usually unintentional findings. These included findings observed upon routine medical checkups, computed tomography, or abdominal echography during examination for other diseases (incidental detection group) and cases referred to our department for renal dysfunction (renal dysfunction group), and "other" group. We compared the renal dysfunction group and the incidental detection group.

RESULTS

The estimated glomerular filtration rate (eGFR) at diagnosis was significantly higher in the incidental detection group. The TKV was significantly lower in the incidental detection group than in the other group. The number of patients with eGFR > 45 mL/min/1.73 m, for which tolvaptan was safe and effective, was significantly higher in the incidental detection group than in the renal dysfunction group.

CONCLUSION

Our study shows that medical checkup enables early detection of ADPKD. This is important because ADPKD may have serious complications. The present study did not examine the age at which abdominal echography screening for the early detection of ADPKD was more useful or cost-effective; thus, further research is needed to ascertain this.

摘要

引言

常染色体显性遗传性多囊肾病(ADPKD)是最常见的遗传性肾病。尽管体检时的腹部超声检查可能对ADPKD的早期检测有效,但尚无关于在体检时早期检测出ADPKD的报道。我们研究了由于ADPKD诊断触发因素的不同,诊断时肾功能和总肾体积(TKV)是否存在差异。

方法

纳入2010年1月1日至2020年12月31日期间在岛根大学医院肾内科诊断为ADPKD的34例患者。肾囊肿的诊断触发因素通常是偶然发现。这些包括在常规体检、计算机断层扫描或检查其他疾病时的腹部超声检查中观察到的结果(偶然发现组)以及因肾功能不全转诊至我科的病例(肾功能不全组)和“其他”组。我们比较了肾功能不全组和偶然发现组。

结果

偶然发现组诊断时的估计肾小球滤过率(eGFR)显著更高。偶然发现组的TKV显著低于其他组。对于托伐普坦安全有效的eGFR>45 mL/min/1.73 m²的患者数量,偶然发现组显著高于肾功能不全组。

结论

我们的研究表明体检能够早期检测出ADPKD。这很重要,因为ADPKD可能会有严重并发症。本研究未探讨腹部超声筛查ADPKD早期检测更有用或更具成本效益的年龄;因此,需要进一步研究来确定这一点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e093/8572515/2b17ba17e0da/cureus-0013-00000018595-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e093/8572515/376e17ba13da/cureus-0013-00000018595-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e093/8572515/2b17ba17e0da/cureus-0013-00000018595-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e093/8572515/376e17ba13da/cureus-0013-00000018595-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e093/8572515/2b17ba17e0da/cureus-0013-00000018595-i02.jpg

相似文献

1
Detection of Autosomal Dominant Polycystic Kidney Disease by Medical Checkup at an Early Stage.通过体检早期检测常染色体显性多囊肾病
Cureus. 2021 Oct 8;13(10):e18595. doi: 10.7759/cureus.18595. eCollection 2021 Oct.
2
The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.成人常染色体显性多囊肾病患者血清血管生成生长因子与肾脏结构和功能的关系
Int Urol Nephrol. 2018 Jul;50(7):1293-1300. doi: 10.1007/s11255-018-1866-1. Epub 2018 Apr 13.
3
Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations.托伐普坦对不同基因突变的常染色体显性多囊肾病患者肾脏受累的影响。
Clin Exp Nephrol. 2021 Mar;25(3):251-260. doi: 10.1007/s10157-020-01988-4. Epub 2020 Nov 3.
4
Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.托伐普坦治疗日本晚期常染色体显性遗传性多囊肾病患者的效果。
J Nephrol. 2018 Dec;31(6):961-966. doi: 10.1007/s40620-018-0545-8. Epub 2018 Oct 24.
5
Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.托伐普坦对不同肾功能水平常染色体显性多囊肾病个体的短期疗效。
Am J Kidney Dis. 2015 Jun;65(6):833-41. doi: 10.1053/j.ajkd.2014.11.010. Epub 2015 Jan 15.
6
Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.在疾病早期,高血压型常染色体显性多囊肾病患者的血浆代谢物和脂质与肾功能和肾脏体积相关。
BMC Nephrol. 2019 Feb 25;20(1):66. doi: 10.1186/s12882-019-1249-6.
7
Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.托伐普坦治疗常染色体显性多囊肾病患者时与总肾体积增长率无关的肾功能保存。
Clin Exp Nephrol. 2021 May;25(5):467-478. doi: 10.1007/s10157-020-02009-0. Epub 2021 Jan 20.
8
Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.托伐普坦治疗常染色体显性遗传多囊肾病:三年经验。
Clin J Am Soc Nephrol. 2011 Oct;6(10):2499-507. doi: 10.2215/CJN.03530411. Epub 2011 Sep 8.
9
Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.常染色体显性遗传多囊肾病患者在 CKD 1-4 期的健康相关生活质量:一项横断面研究。
Am J Kidney Dis. 2014 Feb;63(2):214-26. doi: 10.1053/j.ajkd.2013.08.017. Epub 2013 Nov 1.
10
Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.托伐普坦治疗对常染色体显性多囊肾病肾功能下降的长期益处建模:使用常染色体显性多囊肾病结局模型的探索性分析
BMC Nephrol. 2019 Apr 23;20(1):136. doi: 10.1186/s12882-019-1290-5.

引用本文的文献

1
Clinical and genetic study of a Chinese family affected by both amyotrophic lateral sclerosis and autosomal dominant polycystic kidney disease.一个同时患有肌萎缩侧索硬化症和常染色体显性遗传性多囊肾病的中国家庭的临床与遗传学研究。
Front Neurol. 2022 Oct 20;13:1004909. doi: 10.3389/fneur.2022.1004909. eCollection 2022.

本文引用的文献

1
Cost-Effectiveness of Behavior Modification Intervention for Patients With Chronic Kidney Disease in the FROM-J Study.FROM-J 研究中慢性肾脏病患者行为修正干预的成本效益。
J Ren Nutr. 2021 Sep;31(5):484-493. doi: 10.1053/j.jrn.2020.12.008. Epub 2021 Mar 18.
2
Analysis of Nationwide Data to Determine the Incidence and Diagnosed Prevalence of Autosomal Dominant Polycystic Kidney Disease in the USA: 2013-2015.分析美国全国性数据以确定2013 - 2015年常染色体显性多囊肾病的发病率和诊断患病率
Kidney Dis (Basel). 2019 Mar;5(2):107-117. doi: 10.1159/000494923. Epub 2019 Jan 9.
3
Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing.
人群测序估算多囊肾病和多囊肝病的患病率。
J Am Soc Nephrol. 2018 Oct;29(10):2593-2600. doi: 10.1681/ASN.2018050493. Epub 2018 Aug 22.
4
The prevalence of autosomal dominant polycystic kidney disease (ADPKD): A meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition.常染色体显性多囊肾病(ADPKD)的患病率:对欧洲文献的荟萃分析及意大利摩德纳省的患病率评估表明,ADPKD是一种罕见且诊断不足的疾病。
PLoS One. 2018 Jan 16;13(1):e0190430. doi: 10.1371/journal.pone.0190430. eCollection 2018.
5
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.多中心、开放标签、扩展试验,旨在评估托伐普坦早期与延迟治疗常染色体显性多囊肾病的长期疗效和安全性:TEMPO 4:4 试验。
Nephrol Dial Transplant. 2018 Mar 1;33(3):477-489. doi: 10.1093/ndt/gfx043.
6
Educational Interventions for Patients With CKD: A Systematic Review.慢性肾脏病患者的教育干预:系统评价。
Am J Kidney Dis. 2016 Sep;68(3):353-70. doi: 10.1053/j.ajkd.2016.01.022. Epub 2016 Mar 26.
7
Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease.早期转诊至肾脏专科服务以预防进展至终末期肾病。
Cochrane Database Syst Rev. 2014 Jun 18(6):CD007333. doi: 10.1002/14651858.CD007333.pub2.
8
Tolvaptan in patients with autosomal dominant polycystic kidney disease.托伐普坦治疗常染色体显性遗传多囊肾病。
N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3.
9
Prospective change in renal volume and function in children with ADPKD.常染色体显性多囊肾病患儿肾脏体积和功能的前瞻性变化
Clin J Am Soc Nephrol. 2009 Apr;4(4):820-9. doi: 10.2215/CJN.02810608.
10
Slowing renal function decline in chronic kidney disease patients after nephrology referral.肾病科转诊后慢性肾病患者肾功能下降速度减缓
Nephrology (Carlton). 2008 Dec;13(8):730-6. doi: 10.1111/j.1440-1797.2008.01023.x. Epub 2008 Nov 17.